Key statistics
On Saturday, BioMarin Pharmaceutical Inc (B1MR34:SAO) closed at 156.63, 12.55% above the 52 week low of 139.16 set on Nov 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 156.63 |
|---|---|
| High | 156.63 |
| Low | 156.63 |
| Bid | 139.49 |
| Offer | 187.00 |
| Previous close | 155.20 |
| Average volume | 269.57 |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 14 2026 00:45 GMT.
More ▼
Press releases
- BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
- BioMarin Announces Closing of Private Offering of Senior Notes
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer
- BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
- Veeva and BioMarin Form Long-Term Strategic Partnership
- Veeva and BioMarin Form Long-Term Strategic Partnership
- BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
More ▼
